Portolan Capital Management LLC Reduces Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Portolan Capital Management LLC lessened its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 33.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 205,365 shares of the company's stock after selling 102,734 shares during the period. Portolan Capital Management LLC owned approximately 0.85% of OrthoPediatrics worth $4,760,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Wellington Management Group LLP raised its holdings in shares of OrthoPediatrics by 20.2% in the 4th quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock valued at $24,601,000 after purchasing an additional 178,078 shares in the last quarter. Kennedy Capital Management LLC raised its stake in OrthoPediatrics by 129.8% in the fourth quarter. Kennedy Capital Management LLC now owns 249,978 shares of the company's stock valued at $5,794,000 after buying an additional 141,174 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in OrthoPediatrics by 57.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company's stock worth $3,918,000 after buying an additional 61,412 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of OrthoPediatrics by 204.8% during the 4th quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company's stock worth $992,000 after acquiring an additional 28,768 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of OrthoPediatrics in the 4th quarter valued at about $528,000. Institutional investors and hedge funds own 69.05% of the company's stock.

OrthoPediatrics Stock Performance

Shares of KIDS stock traded up $0.41 during midday trading on Friday, hitting $21.00. The company had a trading volume of 103,576 shares, compared to its average volume of 198,451. OrthoPediatrics Corp. has a 52-week low of $20.26 and a 52-week high of $35.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The company's 50 day simple moving average is $23.87 and its 200 day simple moving average is $24.58. The stock has a market cap of $510.03 million, a price-to-earnings ratio of -17.07 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The company had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter in the prior year, the firm earned ($0.23) EPS. Research analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, insider Gregory A. Odle sold 5,359 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the transaction, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company's stock, valued at approximately $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,732 shares of company stock valued at $589,978. 31.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Lake Street Capital began coverage on OrthoPediatrics in a report on Monday, April 7th. They issued a "buy" rating and a $37.00 price target for the company. Stifel Nicolaus dropped their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Truist Financial decreased their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $37.00.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.